Concentrations and effects of zopiclone are greatly reduced by rifampicin

British Journal of Clinical Pharmacology

Volumn 43, Issue 5, 1997, Pages 471-474

  Villikka, K ^a   Kivisto K T ^a   Lamberg, T S ^a   Kantola, T ^a   Neuvonen, P J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

enzyme induction; interaction; pharmacokinetics; rifampicin; zopiclone

Indexed keywords

RIFAMPICIN; ZOPICLONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL FLICKER FUSION; CROSSOVER PROCEDURE; CURVE FITTING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG HALF LIFE; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL;

EID: 0030919660     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00579.x     Document Type: Article

References (16)

1. Fernandez C, Martin C, Gimenez F, Farinott R. Clinical pharmacokinetics of zopiclone. Clin Pharmacokinet 1995; 29: 431-441.
2. Aranko K, Luurila H, Backman JT, Neuvonen PJ, Olkkola KT. The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone. Br J Clin Pharmacol 1994; 38: 363-367.
3. Jalava KM, Olkkola KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. Eur J Clin Pharmacol 1996; 51: 331-334.
4. Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet 1992; 22: 47-65.
5. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996; 59: 7-13.
6. Villikka K, Kivistö KT, Backman JT, Olkkola KT, Neuvonen PJ. Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther 1997; 61: 8-14.
7. le Liboux A, Frydman A, Gaillot J. Simultaneous determination of zopiclone and its two major metabolites (n-oxide and n-desmethyl) in human biological fluids by reversed-phase high performance liquid chromatography. J Chromatogr 1987; 417: 151-158.
8. Boniface PJ, Martin IC, Nolan SL, To Tan S. Development of a method for the determination of zopiclone in whole blood. J Chromatogr 1992; 584: 199-206.
9. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampicin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90: 1871-1878.
10. Ohnhaus EE, Brockmeyer N, Dylewicz P, Habicht H. The effect of antipyrine and rifampicin on the metabolism of diazepam. Clin Pharmacol Ther 1987; 42: 148-156.
11. Brockmeyer NH, Mertins L, Klimek K, Goos M, Ohnhaus EE. Comparative effects of rifampin and/or probenecid on the pharmacokinetics of temazepam and nitrazepam. Int J Clin Pharmacol Ther Toxicol 1990; 28: 387-393.
12. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989; 36: 89-96.
13. Gaillot J, Heusse D, Houghton GW, Marc Aurele J, Dreyfus JF. Pharmacokinetics and metabolism of zopiclone. Pharmacology 1983; 27(Suppl. 2): 76-91.
14. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 55: 481-485.
15. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56: 601-607.
16. Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ. Concentrations and effects of oral midazolam are greatly reduced in patients on carbamazepine or phenytoin. Epilepsia 1996; 37: 253-257.